TORONTO, Feb. 26,
2025 /PRNewswire/ -- Recently, in response to
numerous questions from the capital market regarding Visionary
Holdings (Nasdaq Stock Code: GV), the company has specifically
issued this press release with the aim of providing a comprehensive
and clear response to these concerns and showcasing the company's
stable development trend and broad prospects.
The company has always adhered to the mission of "Innovative
Medical Technology, Protecting Human Health" and has the vision of
becoming a "Global Leader in Precision Medicine." Driven by this
mission and vision, the company has been continuously exploring and
making proactive efforts in the field of biomedicine, striving to
bring more efficient and precise medical solutions to patients
around the world.
In terms of finance, the company's current revenue mainly comes
from the transformation of phased achievements of existing
businesses. Although the current revenue scale has not yet reached
the explosive growth stage, with the gradual commercialization of
core products, there is a strong expectation for revenue growth.
The R&D expenditure has maintained a reasonable and necessary
investment level over the past few years, accounting for
approximately 15% of the total expenditure each year. It is mainly
concentrated in the key area of early cancer screening research and
development. The company's profitability is steadily increasing.
Through optimizing the cost structure and improving operational
efficiency, it has achieved positive growth in marginal profit. In
terms of sources of funds, the company mainly relies on the cash
reserves accumulated in the early stage, long-term credit
cooperation with financial institutions, and continuous capital
injection from strategic investors to ensure sufficient financial
support for various R&D and investment activities. Currently,
the debt level is within a reasonable range in the industry, and
the financial structure is stable.
Facing fierce market competition, Visionary Holdings has unique
competitiveness in innovation ability and R&D speed. The
company focuses on breakthroughs in cutting-edge technologies in
niche areas, with early cancer screening and targeted detection as
its core, and adopts a differentiated competition strategy. For
example, in the field of home cancer detection technology, the
company's developed rapid home detection technologies for cervical
cancer and colorectal cancer have entered the clinical trial stage
and are expected to be officially launched on the market within 18
months. The commercialization model will adopt a combination of B2B
and B2C. It will not only establish cooperation with hospitals,
clinics, and pharmacies but also directly sell to consumers through
online channels. The company's detection technology focuses on
detecting precancerous lesions. It is fast and convenient, allowing
self-testing at home, and the results can be obtained within 15
minutes. With a lower detection cost, it has stronger market
competitiveness.
In terms of the profit model, in addition to the above-mentioned
commercialization path of cancer screening technology, the company
will also expand its profit channels through means such as
technology licensing and joint development. For future expansion
plans, the company's funds mainly come from diversified financing
channels, including strategic investment, bond financing, etc.
While ensuring the capital demand, it will carefully plan equity
financing to minimize the dilution impact on existing
shareholders.
Visionary Holdings has always adhered to the development concept
of rigor and innovation. Under the guidance of the mission of
"Innovative Medical Technology, Protecting Human Health," it is
striding forward towards the vision of becoming a "Global Leader in
Precision Medicine." The company is confident that with its solid
technical strength, reasonable financial planning, and clear market
strategy, it will achieve greater success in both the capital
market and the medical field, create long-term value for
shareholders, and contribute to the development of the global
medical cause.
View original
content:https://www.prnewswire.com/news-releases/visionary-holdings-deeply-responding-to-the-concerns-of-the-capital-market-and-demonstrating-solid-development-strength-302385119.html
SOURCE Visionary Holdings Inc.
